Neuren Pharmaceuticals Reports Strong Q3 Financial Growth
Company Announcements

Neuren Pharmaceuticals Reports Strong Q3 Financial Growth

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals has announced robust financial progress in Q3 2024, with DAYBUE™ achieving net sales surpassing US$250 million, triggering a US$50 million sales milestone payment. Additionally, Neuren will benefit from a one-third share of the US$150 million sale of a Priority Review Voucher by Acadia Pharmaceuticals. The company’s expected full-year income ranges between A$216 million and A$218 million, bolstered by royalties, milestone payments, and interest income.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Gains from Voucher Sale
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Updates Policy Amid Financial Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App